Washington, Jun 14 (EFE).- The Covid-19 vaccine developed by American firm Novavax has proven safe and highly effective in high-risk patients and against new variants of the virus.
The Maryland-based company issued a statement Monday revealing the vaccine’s 93% efficacy in preventing infections of the major Covid-19 variants, as well as 91% efficacy in high-risk patients.
NVX-CoV2373, which contains the virus’ spike protein, is undergoing phase III of clinical trials with a sample of 29,960 patients in the United States and Mexico.
“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” said Stanley Erck, president and CEO of Novavax.
“These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection.”
The company intends to apply for FDA emergency use authorization in the third quarter of 2021, once the final phases of the clinical trial are over and the company is ready to comply with US manufacturing and control requirements.
“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines,” Erck said.
Novavax could produce up to 100 million doses every month by the end of the third quarter of 2021, and 150 million monthly by the end of the year.
President of research and development Gregory M. Glenn said: “The data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus.” EFE